MorphoSys shares soar over Novartis bid speculation; GKS moves forward with Phase II lupus, psoriasis studies;

 @FierceBiotech: Pfizer partner Protalix soars on sale speculation. Report | Follow @FierceBiotech

@JohnCFierce: So Elan has $3.25B to play with? Will they blow it? Analysis | Follow @JohnCFierce

@RyanMFierce: No surprise here. HISUN doesn't want exclusive license to Celsion's ThermoDox for the China market. Release | Follow @RyanMFierce

> Belgian Galapagos said GlaxoSmithKline ($GSK) plans to initiate Phase II studies with a therapy to treat systemic lupus erythematosus and chronic plaque psoriasis. Release

> Zheijang HISUN Pharmaceutical Company does not plan to pursue the exclusive option to license Celsion Corporation's ($CLSN) ThermoDox for the greater China market. Release

> In light of speculation that its shareholder Novartis ($NVS) might make a bid on the company, shares of MorphoSys, a German biotechnology company, rose to as much as 5.4% to €34.70 ($46.90)--the highest since March 2001. Story

Pharma News

@FiercePharma: GSK to hack jobs in Europe where austerity has taken toll. Report | Follow @FiercePharma

@EricPFierce: With sale of Tysabri rights to Biogen Idec, Elan is now flush with cash and looking for something to buy. News | Follow @EricPFierce

@AlisonBFierce: Merck and GlaxoSmithKline will work with the GAVI Alliance to provide low-cost HPV vaccines to developing countries. Article | Follow @AlisonBFierce

> Merck loses 'bellwether' Fosamax case. Article

> Is Hospira primed for a takeover? News

Medical Device News

 @FierceMedDev: Exosome draws $5M in financing for molecular Dx work. Item | Follow @FierceMedDev

 @MarkHFierce: House Majority Leader Eric Cantor has revived the device tax repeal push, as part of Republicans' new platform. Story | Follow @MarkHFierce

 @DamianFierce: Allergan is looking to sell off its Lap-Band business as revenues continue to plummet. News | Follow @DamianFierce

> HeartMate sales propel Thoratec's Q4 revenue jump. Article

> Zoll gains Japan's sign-off for intravascular temperature management device. Report

Drug Delivery News

> Cloaked nanoparticles look like blood cells, carry drugs. Story

> FDA to review BTG's varicose vein foam injection. News

> Rockwell shows iron delivery drug for dialysis improves treatment. Article

> Langer's Kala scores Cystic Fibrosis Foundation grant. Report

Biomarkers News

> Brain biomarker may help open door to personalized depression drugs. Report

> FDA will make use of GVK biomarker database. Item

> Biomarker could be key to MS Dx and targeted treatment. Article

> Molecules that could predict cancer growth detected. News

> Researcher names protein as plausible autism biomarker. Story

And Finally… NASA has released the first photos of the "comet of the century." Story

Suggested Articles

Across its 15-year history, Omega Funds has a hand in a clutch of high-profile biotechs such as Editas Medicine and Juno Therapeutics.

After Novartis’ near $10 billion buyout of The Medicines Company, many thought cardiovascular therapies were hot again.

Mutations in RIPK1 can cause uncontrolled cell death and inflammation, researchers discovered by studying families with an autoimmune disorder.